Processed data and statistics

Each sheet contains data and statistics generated for the research. Refer to the table legends bellow.

Supplementary Table S1. Core microbiome in gut.

Supplementary Table S2. Core microbiome in lung.

Supplementary Table S3. Adjacency matrix of gut and lung microbiome in healthy controls.

Supplementary Table S4. Adjacency matrix of gut and lung microbiome in patients with TB before treatment.

Supplementary Table S5. Adjacency matrix of gut and lung microbiome in patients with TB after treatment.

Supplementary Table S6. Node score of gut and lung microbiome in healthy controls.

Supplementary Table S7. Node score of gut and lung microbiome in patients with TB before treatment.

Supplementary Table S8. Node score of gut and lung microbiome in patients with TB after treatment.

Supplementary Table S9. Significant results from differential abundance analysis of gut microbiota between HCs and patients with TB before treatment in the gut. Log fold change (logFC) represents the relative abundance in patients with TB compared to healthy controls. The logFC, p-values, and false discovery rates (FDR) were obtained from ANCOM-BC, and linear discriminant analysis (LDA) scores were calculated using LEfSe.

Supplementary Table S10. Significant results from differential abundance analysis of gut microbiota between HCs and patients with TB before treatment in the lung. The logFC represents the log-transformed expression values of patients with TB relative to those of healthy controls (HC). The logFC, p-values, and false discovery rates (FDR) were obtained from ANCOM-BC, while the linear discriminant analysis (LDA) scores were derived from LEfSe.

Supplementary Table S11. Significant results from differential abundance analysis of gut microbiota between patients with TB before and after treatment in the gut. The logFC represents the log-transformed expression values of patients with TB after treatment relative to those of patients with TB before treatment. The logFC, p-values, and false discovery rates (FDR) were obtained from ANCOM-BC, while the linear discriminant analysis (LDA) scores were derived from LEfSe.

Supplementary Table S12. Significant results from differential abundance analysis of gut microbiota between patients with TB before and after treatment in the lung. The logFC represents the log-transformed expression values of patients with TB after treatment relative to those of patients with TB before treatment. The logFC, p-values, and false discovery rates (FDR) were obtained from ANCOM-BC, while the linear discriminant analysis (LDA) scores were derived from LEfSe.

Supplementary Tables S13. Taxa clustering results in healthy controls.

Supplementary Tables S14. Taxa clustering results in patients with TB before treatment.

Supplementary Tables S15. Taxa clustering results in patients with TB after treatment.